利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

314 条记录 (耗时 0.051 秒)

    Anti-CD74 Immunoconjugates and Methods of Use
    61.
    发明申请
    Anti-CD74 Immunoconjugates and Methods of Use 有权
    抗CD74免疫缀合物及其使用方法

    公开(公告)号：US20100272636A1

    公开(公告)日：2010-10-28

    申请号：US12789575

    申请日：2010-05-28

    申请人： John C. Byrd ,  David M. Goldenberg ,  Hans J. Hansen

    发明人： John C. Byrd ,  David M. Goldenberg ,  Hans J. Hansen

    IPC分类号： A61K39/44 ,  A61K9/127 ,  A61K51/12 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  A61P37/06

    CPC分类号： A61K47/48823 ,  A61K39/395 ,  A61K47/6907 ,  A61K47/6913 ,  A61K51/1234 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2833 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/73 ,  G01N33/574 ,  G01N2333/70596 ,  G01N2800/245 ,  A61K2300/00

    摘要： Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing apoptosis of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions.

    摘要翻译： 公开了包含抗CD74免疫缀合物和任选的治疗和/或诊断剂的组合物。 在优选的实施方案中，免疫偶联物包含缀合至脂质体或胶束的一种或多种抗CD74抗体或其抗原结合片段。 还公开了在诊断和治疗过程中制备免疫缀合物和使用免疫缀合物的方法。 在某些优选实施方案中，治疗方法包括向具有表达CD74的疾病的受试者施用抗CD74免疫偶联物，从而诱导表达CD74的细胞的凋亡。 在更优选的实施方案中，CD74免疫缀合物能够在不存在任何其它治疗剂的情况下诱导细胞死亡，尽管可以任选地在施用抗CD74免疫缀合物之前，之后或之后施用这些试剂。 组合物可以是用于施用抗CD74免疫缀合物或组合物的试剂盒的一部分。

    METHODS AND COMPOSITIONS FOR IMMUNOTHERAPY AND DETECTION OF INFLAMMATORY AND IMMUNE-DYSREGULATORY DISEASE, INFECTIOUS DISEASE, PATHOLOGIC ANGIOGENESIS AND CANCER
    66.
    发明申请
    METHODS AND COMPOSITIONS FOR IMMUNOTHERAPY AND DETECTION OF INFLAMMATORY AND IMMUNE-DYSREGULATORY DISEASE, INFECTIOUS DISEASE, PATHOLOGIC ANGIOGENESIS AND CANCER 审中-公开

    公开(公告)号：US20080241141A1

    公开(公告)日：2008-10-02

    申请号：US11929315

    申请日：2007-10-30

    申请人： David M. Goldenberg ,  Hans J. Hansen

    发明人： David M. Goldenberg ,  Hans J. Hansen

    IPC分类号： A61K38/02 ,  A61K39/395 ,  A61P37/00

    CPC分类号： A61K39/3955 ,  A61K31/513 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/4866 ,  A61K39/40 ,  A61K45/06 ,  A61K49/0002 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/1203 ,  C07K16/24 ,  C07K16/241 ,  C07K16/248 ,  C07K16/2803 ,  C07K16/2896 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/734

    摘要： Methods and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases, using multispecific antagonists that target at least two different markers are disclosed. The different targets include (i) proinflammatory effectors of the innate immune system, (ii) coagulation factors, and (iii) targets specifically associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, wherein the targets included in group (iii) are neither a proinflammatory effector of the immune system nor a coagulation factor. When the multispecific antagonist reacts specifically with a target associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, it also binds specifically with at least one proinflammatory effector of the immune system or at least one coagulation factor. Thus, the multispecific antagonist contains at least one binding specificity related to the diseased cell or condition being treated and at least one specificity to a component of the immune system, such as a receptor or antigen of B cells, T cells, neutrophils, monocytes and macrophages, and dendritic cells, a modulator of coagulation, or a proinflammatory cytokine. The multispecific antagonists are used in the treatment of various diseases that are generated or exacerbated by, or otherwise involve, proinflammatory effectors of the innate immune system or coagulation factors. Such diseases more particularly include acute and chronic inflammatory disorders, autoimmune diseases, giant cell arteritis, septicemia and septic shock, coagulopathies (including diffuse intravascular coagulation), neuropathies, graft versus host disease, infectious diseases, acute respiratory distress syndrome, granulomatous diseases, transplant rejection, asthma, cachexia, myocardial ischemia, and atherosclerosis. Other diseases also responsive to these therapies include cancers and conditions with pathological angiogenesis.

    Immunotherapy for chronic myelocytic leukemia
    67.
    发明授权
    Immunotherapy for chronic myelocytic leukemia 有权
    免疫治疗慢性骨髓性白血病

    公开(公告)号：US07323168B2

    公开(公告)日：2008-01-29

    申请号：US10853150

    申请日：2004-05-26

    申请人： David M. Goldenberg ,  Hans J. Hansen

    发明人： David M. Goldenberg ,  Hans J. Hansen

    IPC分类号： A61K39/395

    CPC分类号： C07K16/2803

    摘要： Immunotherapy utilizing naked anti-granulocyte antibodies provides an effective means for treating chronic myelocytic leukemia (CML). Such antibodies can be administered alone or in combination with other therapies, such as immunoconjugates or chemotherapeutics. In either format, an effective therapy for treating CML is provided, which avoids the toxic side-effects typically associated with cancer therapy. The disclosed immunotherapy also is effective for treating acute myelocytic leukemia (AML) when co-administered with inducing agents which induce expression of antigens minimally displayed on the surface of myeloblasts.

    摘要翻译： 使用裸抗粒细胞抗体的免疫治疗提供治疗慢性骨髓性白血病（CML）的有效手段。 这样的抗体可以单独施用或与其它疗法组合施用，例如免疫缀合物或化学治疗剂。 以任一格式，提供治疗CML的有效治疗方法，其避免通常与癌症治疗相关的毒副作用。 当与诱导表达共同施用时，所公开的免疫治疗也可有效治疗急性髓细胞性白血病（AML），所述诱导剂诱导表达最低限度地显示在原粒细胞表面上。

    Monoclonal antibody hPAM4
    69.
    发明授权
    Monoclonal antibody hPAM4 有权
    单克隆抗体hPAM4

    公开(公告)号：US07282567B2

    公开(公告)日：2007-10-16

    申请号：US10461885

    申请日：2003-06-16

    申请人： David M. Goldenberg ,  Hans J. Hansen ,  Zhengxing Qu

    发明人： David M. Goldenberg ,  Hans J. Hansen ,  Zhengxing Qu

    IPC分类号： C07K16/00

    CPC分类号： A61K49/0008 ,  A61K47/68 ,  A61K51/1057 ,  A61K2039/505 ,  C07K14/4748 ,  C07K16/2896 ,  C07K2317/24

    摘要： This invention relates to monovalent and multivalent, monospecific antibodies and to multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these antibodies has two or more binding sites where these binding sites have affinity towards different epitopes on a target antigen or different target antigens, or have affinity towards a target antigen and a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional antibodies in a host. More specifically, the present invention relates to the tumor-associated antibody designated PAM4. The invention further relates to humanized and human PAM4 antibodies, and the use of such antibodies in diagnosis and therapy.

    摘要翻译： 本发明涉及单价和多价单特异性抗体和多价多特异性抗体。 这些抗体的一个实施方案具有一个或多个相同的结合位点，其中每个结合位点与靶抗原或靶抗原上的表位结合。 这些抗体的另一个实施方案具有两个或多个结合位点，其中这些结合位点对靶抗原或不同靶抗原上的不同表位具有亲和力，或对靶抗原和半抗原具有亲和力。 本发明还涉及可用于在宿主中表达这些功能性抗体的重组载体。 更具体地说，本发明涉及称为PAM4的肿瘤相关抗体。 本发明还涉及人源化和人类PAM4抗体，以及这些抗体在诊断和治疗中的用途。